1.EFFECT OF SPIRULINA PLATENSIS ON BLOOD CELLS IN THE CHEMOTHERAPY OF ACUTE LEUKEMIA
Chinese Journal of Marine Drugs 1994;0(04):-
Fifty-two cases of acute leukemia were treated with chemotherapy, and forty-one cases in combination vrith Spirulina platensis. After the therapy, the patient's bone marrow was inhibited. The inhibition period of bone marrow was shortened and the recovery period was advanced in the combined Spirylina platensis therapy, the level of peripheral blood cells was raised. The results suggest that the combined spirulina platensis therapy in chemotherapy could accelerate the recovery of the normal hematopoiesis and increase the amounts of blood cells.
2.Blood pressure control and glucose metabolism status in hypertension specialty clinics in China
Ningling SUN ; Hongyi WANG ; Yong HUO
Chinese Journal of Internal Medicine 2013;52(8):654-658
Objective To investigate blood pressure control the glucose metabolism,cardiovascular risk factors of patients who were regularly followed up at professional hypertension clinics in China.Methods A cross-sectional survey was conducted in 32 004 patients from 127 professional hypertension clinics across China.The questionnaires included case history and related treatment physical examination and laboratory biochemical tests were also taken at the same time.Results The mean blood pressure of overall population was (151 ± 13)/(92 ± 10) mm Hg(1 mm Hg =0.133 kPa).Totally 3424 patients (10.7%) had never taken any anti-hypertension medicine.Among patients treated with anti-hypertension drugs,19 818 were of mono-therapy (69.3%) and 8762 were of combination therapy.The most frequently used drug was reninangiotensin system inhibitor,followed by calcium-channel blocker.Fixed compound preparations accounted for 15.6%.The overall blood pressure control rate (< 140/90 mm Hg) was 26.8%,among them,27.7%,30.0%,25.4% and 21.3% patients were complicated with coronary heart disease,diabetes mellitus,kidney diseases and cerebral stroke respectively.About 70.3% hypertensive patients had abnormal glucose metabolism whose mean glycosylated hemoglobin (GHbA1 c) was 7.84%,which was significantly higher than 7.0%,the target value defined by ADA.Even among them,20.2% patients have never received any anti-diabetic drugs.Low-risk and medium-risk patients accounted for 16.0%.Totally 48.0% patients were classified in high-risk group and 36.0% in very high risk group.About half of all patients had different target organ dysfunction.About 49.0% patients had associated comorbidities.Conclusions Co-existence of hypertension and abnormal glucose metabolism is common in Chinese population.Among these patients,target organ dysfunction and comorbidities are prevalent,but blood pressure is only effectively controlled in less than 30% patients.Low proportion of combination therapy is one of the reasons for unsatisfied control of blood pressure.It indicates that effective management of hypertension is urgent.
3.Clinical study of recombinant human endostatin with GP regimen in the treatment of advanced non-small-cell lung cancer
Ming GU ; Limin GENG ; Hongyi SUN
Cancer Research and Clinic 2011;23(10):690-692
Objective To evaluate the efficacy and security of combined recombinant human endostatin with GP chemotherapy for the treatment of advanced non-small-cell lung cancer (NSCLC).Methods Non- randomized concurrent control was used.32 patients were treated by recombinant human endostatin combined with chemotherapy as test group,40 patients of control group only received chemotherapy.The response rate (RR),the clinical benefit rate (CBR) and the time to progression (TTP) were observed.Results The total RR in two groups were 40.6 % and 20.0 % (x2 =3.66,P =0.07).The total CBR were 68.8 % and 42.5 % (x2 =4.93,P =0.034).The total time to progression were 5.2 months and 3.9 months (P =0.042).Incidence of adverse reactions of experimental group and control group was no significant difference.Conclusion Combined recombinant human endostatin and chemotherapy can improve the curative effect (RR,CBR and TTP) of advanced NSCLC.
4.The Significance of Immunoglobulins and Albumin in the Cerebrospinal-fluid (CSF) on Differential Diagnosis of Meningitis
Hongyi XING ; Shenggang SUN ; Yuanwu MEI
Journal of Chinese Physician 2001;0(06):-
61mg/L. Conclusion The destruction of blood-brain barrier in TM and PM was obviously stronger than that in VM. The contents of CSF-Ig and -Alb are helpful to diagnose and differntially diagnose meningitis.
5.PSS IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA
Hongyi WANG ; Wei SUN ; Peirui SHI ;
Chinese Journal of Marine Drugs 1994;0(04):-
Using chemotherapy (DA or HA and ATRA) to treat 22 cases of acute promyelocytic leukemia following to give PSS (100mg/d X 7d) ,the patients complicated with DIC were treated then were given the chemotherapy,combined with PSS to end. The results showed that the complete remission rate of the therapy of APL with PSS was increased to
6.The protection of carbamylated erythropoietin on focal ischemic brain injury
Hongyi XING ; Shenggang SUN ; Yuanwu MEI ; Hai PENG
Chinese Journal of Neurology 2010;43(2):125-129
Objective To study the protection and its mechanism of carbamylated erythropoietin (CEPO) on ischemic brain injury and to compare its function with erythropoietin (EPO).Methods Focal cerebral ischemia/reperfusion was induced by occlusion of the middle cerebral artery (MCAO) using the intraluminal filament technique.The expression of endothelial NO synthase (eNOS) and activated caspase-3 were detected with Western blot.The inducible NO synthase (iNOS) positive cells were detected by immunohistochemistry staining.The apoptotic cell was detected by TUNEL staining.Results The expression of eNOS, iNOS and activated caspase-3 in cerebral cortex significantly increased after MCAO.The influence of CEPO and EPO on eNOS in ischemic cortex were not significantly different.However, the expression of activated caspase-3 markedly dropped from 95.4%±16.7% in group NS to 43.5%±13.1% in group CEPO and 45.1%±11.2% in group EPO (t=5.99 and 6.13,P<0.01).Immunohistochemistry staining revealed iNOS positive cells in ischemic cortex was (3.1±1.9) cells/square, CEPO and EPO remarkably reduced them to (0.7±0.2) cells/square and (0.8±0.2) cells/square, respectively (t=3.08 and 2.95, P < 0.05).The apoptotic cells in ischemic cortex fell from (94.2±15.2) cells/square in group NS to (40.5±9.8) cells/square in group CEPO (t=7.27, P < 0.01), the anti-apoptosis by EPO was similar to CEPO.Conclusion CEPO and EPO have the similar function of anti-apoptosis by inhibiting expression of activated caspase-3 and iNOS.
7.The protective effect of rosuvastatin on ischemic brain injury and its mechanism.
Hongyi, XING ; Shenggang, SUN ; Yuanwu, MEI ; Dirk, HERMAN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2006;26(6):667-9
To study the protective effect of rosuvastatin on ischemic brain injury and its mechanism, focal cerebral ischemia/reperfusion was induced by occlusion of the middle cerebral artery (MCA) using the intra-luminal filament technique. The cerebral blood flow was monitored with laser-Doppler flowmetry (LDF). The slices of brain tissue were stained with cresyl-violet. The cerebral volume of infarction and edema were quantified with ImageJ software. The expressions of endothelial NO synthase (eNOS) and activated caspase-3 were detected with Western blot. The inducible NO synthase (iNOS) positive cells were immunohistochemically observed. The results demonstrated that rosuvastatin (20 mg/kg) could remarkably decrease infarct volume and cerebral edema after MCAO 90 min/reperfusion 24 h. Western blots showed that the expression of eNOS in cerebral cortex before and after ischemia was (100+/-43.3) %, (1668.9+/-112.2) % respectively (P<0.001), rosuvastatin significantly up-regulated the expression of eNOS in non-ischemic cortex (P<0.001), whereas in ischemic cortex of rosuvastatin group the expression of eNOS was (1678.8+/-121.3) %. There was no expression of activated caspase-3 in non-ischemic cortex, nonetheless the expression of activated caspase-3 increased after ischemia, and rosuvastatin significantly diminished it (P<0.01). Immunohistochemistry revealed no iNOS-positive cells in non-ischemic brain area, while in ischemic brain area the number of iNOS positive cells went up, and rosuvastatin could significantly reduced them. Consequently, the mechanisms of rosuvastatin's neural protection on ischemic brain injury are to enhance expression of eNOS, to inhibit expression of iNOS and activated caspase-3.
8.G protein ?_3 subunit C825T polymorphism and essential hypertension in Chinese
Hongyi WANG ; Ningling SUN ; Ying GAO ; Shuqi GOU
Journal of Peking University(Health Sciences) 2003;0(04):-
Objective:To study the relationship between G protein ? 3 subunit ( GNB3 )C825T variant and plasma renin angiotensin system(RAS) activity in Chinese essential hypertensive patients. Methods: Case control method was used. For 408 essential hypertensive patients who were enrolled in the trial groups, we chose 140 normotensives as control group 1 and 61 health persons with hypertensive familial history as control group 2, respectively. PCR-RFLP method was used to measure the C/T polymorphism. The results were observed by agarose gel eletrophoresis. Results: The frequencies of 825T allele were 45.6% to 56.4% in the three groups. Neither GNB3 genotype distribution nor the frequency of T allele was associated with essential hypertension. But patients with TT genotype had higher aldosterone level and lower angiotensin converting enzyme (ACE) activity than patients with CC genotype. Conclusion:In Chinese, patients with TT genotype had higher aldosterone level and lower angiotensin converting enzyme (ACE) activity.
9.The relationship between serum biochemical markers of myocardial damage and prognosis in patients with severe acute pancreatitis
Ming FANG ; Hongke ZENG ; Xiangfan ZHEN ; Hongyi LI ; Cheng SUN
Chinese Journal of Emergency Medicine 2006;0(03):-
0.05),APACHEⅡ score,and mortality were higher than those in negative group(P
10.Discussion on Measures and Institutions of Medical Equipment Management
Ying SUN ; Hongyi ZHANG ; Hong WANG ; Ming YIN ; Zhongjun ZHOU
Chinese Medical Equipment Journal 2004;0(07):-
Institutions and management for some key processes in medical equipment management are described. Desired effect is achieved in practice. Good and efficicent medical equipment management is one of the important factors to guarantee medical quality in hospital. Medical equipment management should be improved with the equipment development.